A recent study showed some benefits to taking SGLT2 inhibitors to treat Type 2 diabetes.
The study compared certain SGLT2 inhibitors with other glucose-lowering drugs (oGLDs).
Results showed patients taking SGLT2 inhibitors to treat Type 2 diabetes were less likely to experience heart attack and stroke than patients using oGLDs.
The study also suggested SGLT2 inhibitors might offer Type 2 diabetes patients certain heart and cardiovascular benefits over oGLDs.
But the study results don’t tell consumers the whole story.
Here’s eight things consumers need to know about the latest SGLT2 inhibitor study:
Dr. Mikhail Kosiborod presented the study results this month at the 67th American College of Cardiology Scientific Sessions in Orlando. The Journal of the American College of Cardiology simultaneously published the study.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(888) 645-1617